

22 Aug 2018 | Analysis

QUOTED. Aug. 22, 2018. Gary Altman.

by

Scottsdale, Ariz.-based Provista Diagnostics is looking at breast cancer with a focus on early detection. The manufacturer's *Videssa* assay aims to rule out breast cancer in women with both dense and non-dense breast tissue, and the firm is providing guidance to physicians in cases where imaging modalities are inconclusive. See what Provista CEO Gary Altman said about it here.

"There are many blood tests out there that indicate they are looking at breast cancer, but many of them are risk factors. Ours is the only one that we are aware of which interrogates proteins, tumor auto-antibodies and serum biomarkers to indicate with a great deal of accuracy the presence of active breast cancer. It is especially useful for women with dense breast tissue for which the radiologists have difficulty interpreting the image or with other women of high risk, that is [with] genomic factors or familial history." – Gary Altman, CEO, Provista Diagnostics Inc.

- Find out more: [Market Intel: Liquid Biopsy II – Emerging Companies Look For Liquid Gold](#)

[Click here](#) for a free trial of *Medtech Insight*